The global bronchodilators market is expected to reach USD 28.75 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 3.29% from 2023 to 2030. The growth of the bronchodilators market is attributed to the increasing geriatric population and rising population with respiratory disorders. Moreover, respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma are more common among the elderly population.
The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders. The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD. For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC’s. This population has an accelerated rate of deterioration in lung function along with intensified mortality rate. As per American Lung Association, 17% of the population with asthma are smokers which is 13.7% in the non-asthmatic population. This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.
Moreover, there are increasing efforts from public and private organizations to increase awareness among the population. International organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are working with public health officials and healthcare professionals worldwide to increase awareness and improve the treatment and prevention of COPD around the world. Moreover, companies such as AstraZeneca, Cipla, Teva, and several others have been trying to spread awareness through social media platforms such as ‘Get Real’, #Laugh4Lungs’, ‘Inhalers are Right for Asthma’, ‘Inhaler is boon for Asthma’, and many more. These campaigns help raise awareness and encourage patients towards using more bronchodilators and enable them to secure their lives by taking preventive measures. Furthermore, the market is expected to grow due to regional market players ongoing R&D efforts to develop an effective treatment for patients with respiratory disorders.
Companies are collaborating to develop novel treatments to address unmet medical needs. This enables businesses to use their resources to help with product development and supply chain improvements. Moreover, a number of players are also focusing on product launches in order to expand their product portfolio. For instance, in September 2021, AstraZeneca started working on a combination formulation of inhaled corticosteroid (ICS) budesonide and beta2-agonist (SABA) albuterol for the treatment of patients with Asthma, which if approved is expected to be the first ICS/SABA combo rescue inhaler for asthma in the U.S.
The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders. The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD. For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC’s. This population has an accelerated rate of deterioration in lung function along with intensified mortality rate. As per American Lung Association, 17% of the population with asthma are smokers which is 13.7% in the non-asthmatic population. This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.
Moreover, there are increasing efforts from public and private organizations to increase awareness among the population. International organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are working with public health officials and healthcare professionals worldwide to increase awareness and improve the treatment and prevention of COPD around the world. Moreover, companies such as AstraZeneca, Cipla, Teva, and several others have been trying to spread awareness through social media platforms such as ‘Get Real’, #Laugh4Lungs’, ‘Inhalers are Right for Asthma’, ‘Inhaler is boon for Asthma’, and many more. These campaigns help raise awareness and encourage patients towards using more bronchodilators and enable them to secure their lives by taking preventive measures. Furthermore, the market is expected to grow due to regional market players ongoing R&D efforts to develop an effective treatment for patients with respiratory disorders.
Companies are collaborating to develop novel treatments to address unmet medical needs. This enables businesses to use their resources to help with product development and supply chain improvements. Moreover, a number of players are also focusing on product launches in order to expand their product portfolio. For instance, in September 2021, AstraZeneca started working on a combination formulation of inhaled corticosteroid (ICS) budesonide and beta2-agonist (SABA) albuterol for the treatment of patients with Asthma, which if approved is expected to be the first ICS/SABA combo rescue inhaler for asthma in the U.S.
Bronchodilators Market Report Highlights
- Beta adrenergic bronchodilators segment held a dominant share in the market in 2022, owing to the increasing number of generic approvals by the FDA to meet the rising demands
- Oral segment is projected to grow at the fastest rate over the forecast period attributable to it being the second most preferred mode of administration amongst clinicians and patients
- Asthma segment held a dominant share of the market in 2022 owing to the increasing prevalence of target diseases worldwide
- North America dominated the market in 2022, which is attributed to the presence of key market players in the region, highly developed healthcare infrastructure, better affordability
Table of Contents
Chapter 1 Methodology And Scope1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.12 List Of Abbreviations
Chapter 2 Bronchodilators Market - Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Bronchodilators Market Variables, Trends & Scope
3.1 Bronchodilators Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.1.1 Global Asthma And Copd Market
3.1.2 Ancillary Market Outlook
3.1.2.1 Branded Generics Market
3.1.2.2 Hospital-Acquired Infection Therapeutics Market
3.2 Penetration And Growth Prospect Mapping
3.3 Market Driver Analysis
3.3.1 Growing Geriatric Population
3.3.2 Increasing Prevalence Of Lung Diseases
3.3.3 Rising Awareness About Treatment Of Lung Diseases
3.3.4. Increase In Number Of Smokers
3.3.5. Escalating R&D Efforts By Players
3.3.6. Heightened Pollution Levels Globally
3.4 Market Restraint Analysis
3.4.1 Long Approvals Times And Stringent Regulations
3.4.2 Adverse Effects Of Bronchodilators
3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
3.6 Porter’s Five Forces Analysis
3.7 Regulatory Framework
Chapter 4 Bronchodilators Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
4.1 Definition And Scope
4.2 Bronchodilators Market: Drug Class Movement Analysis
4.2.1 Beta-Adrenergic Bronchodilators
4.2.1.1 Beta-Adrenergic Bronchodilators Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.2.2 Anticholinergic Bronchodilators
4.2.2.1 Anticholinergic Bronchodilators Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.2.3 Xanthine Derivatives
4.2.3.1 Xanthine Derivatives Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5 Bronchodilators Market - Segment Analysis, By Route Of Administration, 2018 - 2030 (USD Million)
5.1 Bronchodilators Market: Route Of Administration Movement Analysis
5.1.1 Oral
5.1.1.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.2 Nasal (Inhalable)
5.1.2.1 Nasal (Inhalable) Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.1.3 Injectable
5.1.3.1 Injectable Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Bronchodilators Market - Segment Analysis, By End-Use, 2018 - 2030 (USD Million)
6.1 Definition And Scope
6.2 Bronchodilators Market: Disease Movement Analysis
6.2.1 Asthma
6.2.1.1 Asthma Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.2.2 Chronic Obstructive Pulmonary Disease (Copd)
6.2.2.1 Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.2.3 Others
6.2.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Bronchodilators Market - Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2022 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
7.7 North America
7.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. Bronchodilators Market, 2018 - 2030 (USD Million)
7.7.2.2 Key Country Dynamics
7.7.2.3 Regulatory Framework
7.7.2.4 Competitive Scenario
7.7.2.5 Recent Developments
7.7.2.6 Investments Scenario
7.7.3 Canada
7.7.3.1 Canada Bronchodilators Market, 2018 - 2030 (USD Million)
7.7.3.2 Key Country Dynamics
7.7.3.3 Regulatory Framework
7.7.3.4 Competitive Scenario
7.7.3.5 Recent Developments
7.7.3.6 Investments Scenario
7.8 Europe
7.8.1 Europe Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.2.2 Key Country Dynamics
7.8.2.3 Regulatory Framework
7.8.2.4 Competitive Scenario
7.8.2.5 Recent Developments
7.8.2.6 Investments Scenario
7.8.3 Germany
7.8.3.1 Germany Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.3.2 Key Country Dynamics
7.8.3.3 Regulatory Framework
7.8.3.4 Competitive Scenario
7.8.3.5 Recent Developments
7.8.3.6 Investments Scenario
7.8.4 Spain
7.8.4.1 Spain Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.4.2 Key Country Dynamics
7.8.4.3 Regulatory Framework
7.8.4.4 Competitive Scenario
7.8.4.5 Recent Developments
7.8.4.6 Investments Scenario
7.8.5 France
7.8.5.1 France Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.5.2 Key Country Dynamics
7.8.5.3 Regulatory Framework
7.8.5.4 Competitive Scenario
7.8.5.5 Recent Developments
7.8.5.6 Investments Scenario
7.8.6 Italy
7.8.6.1 Italy Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.6.2 Key Country Dynamics
7.8.6.3 Regulatory Framework
7.8.6.4 Competitive Scenario
7.8.6.5 Recent Developments
7.8.6.6 Investments Scenario
7.8.7 Denmark
7.8.7.1 Denmark Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.7.2 Key Country Dynamics
7.8.7.3 Regulatory Framework
7.8.7.4 Competitive Scenario
7.8.7.5 Recent Developments
7.8.7.6 Investments Scenario
7.8.8 Sweden
7.8.8.1 Sweden Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.8.2 Key Country Dynamics
7.8.8.3 Regulatory Framework
7.8.8.4 Competitive Scenario
7.8.8.5 Recent Developments
7.8.8.6 Investments Scenario
7.8.9 Norway
7.8.9.1 Norway Bronchodilators Market, 2018 - 2030 (USD Million)
7.8.9.2 Key Country Dynamics
7.8.9.3 Regulatory Framework
7.8.9.4 Competitive Scenario
7.8.9.5 Recent Developments
7.8.9.6 Investments Scenario
7.9 Asia Pacific
7.9.1 Asia-Pacific Bronchodilators Market, 2018 - 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan Bronchodilators Market, 2018 - 2030 (USD Million)
7.9.2.2 Key Country Dynamics
7.9.2.3 Regulatory Framework
7.9.2.4 Competitive Scenario
7.9.2.5 Recent Developments
7.9.2.6 Investments Scenario
7.9.3 China
7.9.3.1 China Bronchodilators Market, 2018 - 2030 (USD Million)
7.9.3.2 Key Country Dynamics
7.9.3.3 Regulatory Framework
7.9.3.4 Competitive Scenario
7.9.3.5 Recent Developments
7.9.3.6 Investments Scenario
7.9.4 India
7.9.4.1 India Bronchodilators Market, 2018 - 2030 (USD Million)
7.9.4.2 Key Country Dynamics
7.9.4.3 Regulatory Framework
7.9.4.4 Competitive Scenario
7.9.4.5 Recent Developments
7.9.4.6 Investments Scenario
7.9.5 South Korea
7.9.5.1 South Korea Bronchodilators Market, 2018 - 2030 (USD Million)
7.9.5.2 Key Country Dynamics
7.9.5.3 Regulatory Framework
7.9.5.4 Competitive Scenario
7.9.5.5 Recent Developments
7.9.5.6 Investments Scenario
7.9.6 Thailand
7.9.6.1 Thailand Bronchodilators Market, 2018 - 2030 (USD Million)
7.9.6.2 Key Country Dynamics
7.9.6.3 Regulatory Framework
7.9.6.4 Competitive Scenario
7.9.6.5 Recent Developments
7.9.6.6 Investments Scenario
7.9.7 Australia
7.9.7.1 Australia Bronchodilators Market, 2018 - 2030 (USD Million)
7.9.7.2 Key Country Dynamics
7.9.7.3 Regulatory Framework
7.9.7.4 Competitive Scenario
7.9.7.5 Recent Developments
7.9.7.6 Investments Scenario
7.10 Latin America
7.10.1 Latin America Bronchodilators Market, 2018 - 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil Bronchodilators Market, 2018 - 2030 (USD Million)
7.10.2.2 Key Country Dynamics
7.10.2.3 Regulatory Framework
7.10.2.4 Competitive Scenario
7.10.2.5 Recent Developments
7.10.2.6 Investments Scenario
7.10.3 Mexico
7.10.3.1 Mexico Bronchodilators Market, 2018 - 2030 (USD Million)
7.10.3.2 Key Country Dynamics
7.10.3.3 Regulatory Framework
7.10.3.4 Competitive Scenario
7.10.3.5 Recent Developments
7.10.3.6 Investments Scenario
7.10.4 Argentina
7.10.4.1 Argentina Bronchodilators Market, 2018 - 2030 (USD Million)
7.10.4.2 Key Country Dynamics
7.10.4.3 Regulatory Framework
7.10.4.4 Competitive Scenario
7.10.4.5 Recent Developments
7.10.4.6 Investments Scenario
7.11 MEA
7.11.1 MEA Bronchodilators Market, 2018 - 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa Bronchodilators Market, 2018 - 2030 (USD Million)
7.11.2.2 Key Country Dynamics
7.11.2.3 Regulatory Framework
7.11.2.4 Competitive Scenario
7.11.2.5 Recent Developments
7.11.2.6 Investments Scenario
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia Bronchodilators Market, 2018 - 2030 (USD Million)
7.11.3.2 Key Country Dynamics
7.11.3.3 Regulatory Framework
7.11.3.4 Competitive Scenario
7.11.3.5 Recent Developments
7.11.3.6 Investments Scenario
7.11.4 UAE
7.11.4.1 UAE Bronchodilators Market, 2018 - 2030 (USD Million)
7.11.4.2 Key Country Dynamics
7.11.4.3 Regulatory Framework
7.11.4.4 Competitive Scenario
7.11.4.5 Recent Developments
7.11.4.6 Investments Scenario
7.11.5 Kuwait
7.11.5.1 Kuwait Bronchodilators Market, 2018 - 2030 (USD Million)
7.11.5.2 Key Country Dynamics
7.11.5.3 Regulatory Framework
7.11.5.4 Competitive Scenario
7.11.5.5 Recent Developments
7.11.5.6 Investments Scenario
Chapter 8 Bronchodilators Market - Competitive Analysis
8.1 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.2 Strategy Framework
8.3 Market Participation Categorization
8.4 Recent Developments & Impact Analysis, By Key Market Participants
8.5 Company Position Analysis
8.6 List Of Distributors
8.6.1 Key Customers
8.6.2 Public Companies
8.6.3 Private Companies
Chapter 9 Bronchodilators Market - Company Profiles
9.1 Company Profiles
9.1.1 Gsk Plc.
9.1.1.1 Company Overview
9.1.1.2 Financial Performance
9.1.1.3 Product Benchmarking
9.1.1.4 Strategic Initiatives
9.1.2 Astrazeneca
9.1.2.1 Company Overview
9.1.2.2 Financial Performance
9.1.2.3 Product Benchmarking
9.1.2.4 Strategic Initiatives
9.1.3 Teva Pharmaceutical Industries Ltd.
9.1.3.1 Company Overview
9.1.3.2 Financial Performance
9.1.3.3 Product Benchmarking
9.1.3.4 Strategic Initiatives
9.1.4 Cipla Inc.
9.1.4.1 Company Overview
9.1.4.2 Financial Performance
9.1.4.3 Product Benchmarking
9.1.4.4 Strategic Initiatives
9.1.5 Mylan N.V.
9.1.5.1 Company Overview
9.1.5.2 Financial Performance
9.1.5.3 Product Benchmarking
9.1.5.4 Strategic Initiatives
9.1.6 Merck & Co., Inc.
9.1.6.1 Company Overview
9.1.6.2 Financial Performance
9.1.6.3 Product Benchmarking
9.1.6.4 Strategic Initiatives
9.1.7 Novartis Ag
9.1.7.1 Company Overview
9.1.7.2 Financial Performance
9.1.7.3 Product Benchmarking
9.1.7.4 Strategic Initiatives
9.1.8 Boehringer Ingelheim International Gmbh.
9.1.8.1 Company Overview
9.1.8.2 Financial Performance
9.1.8.3 Product Benchmarking
9.1.8.4 Strategic Initiatives
9.1.9 Sun Pharmaceutical Industries Ltd.
9.1.9.1 Company Overview
9.1.9.2 Financial Performance
9.1.9.3 Product Benchmarking
9.1.9.4 Strategic Initiatives
9.1.10 Glenmark Pharmaceuticals Limited
9.1.10.1 Company Overview
9.1.10.2 Financial Performance
9.1.10.3 Product Benchmarking
9.1.10.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Bronchodilators Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 6 Global Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 7 Global Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 8 North America Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
Table 9 North America Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 10 North America Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 11 North America Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 12 U.S. Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 U.S. Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 14 U.S. Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 15 Canada Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 16 Canada Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 Canada Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 18 Europe Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
Table 19 Europe Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 Europe Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Europe Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 22 U.K. Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 23 U.K. Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 24 U.K. Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 25 Germany Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 Germany Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 Germany Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 28 France Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 France Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 France Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 31 Spain Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 32 Spain Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 33 Spain Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 34 Italy Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 Italy Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Italy Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 37 Denmark Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 38 Denmark Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Denmark Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 40 Sweden Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 41 Sweden Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 42 Sweden Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 43 Norway Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 44 Norway Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Norway Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
Table 47 Asia Pacific Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 50 Japan Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 51 Japan Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 Japan Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 53 China Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 China Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 55 China Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 56 Australia Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 57 Australia Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 58 Australia Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 59 Thailand Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 60 Thailand Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 61 Thailand Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 62 India Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 63 India Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 64 India Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 65 South Korea Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 66 South Korea Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 67 South Korea Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 68 Latin America Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
Table 69 Latin America Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 70 Latin America Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 71 Latin America Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 72 Mexico Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 73 Mexico Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 74 Mexico Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 75 Brazil Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 76 Brazil Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 77 Brazil Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 78 Argentina Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 79 Argentina Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 80 Argentina Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 81 MEA Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
Table 82 MEA Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 83 MEA Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 84 MEA Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 85 South Africa Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 86 South Africa Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 87 South Africa Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 91 UAE Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 92 UAE Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 93 UAE Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
Table 94 Kuwait Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
Table 95 Kuwait Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 96 Kuwait Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Bronchodilators market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Bronchodilators market snapshot
Fig. 10 Penetration and growth prospect mapping for application, 2022 (USD million)
Fig. 11 Market Dynamics
Fig. 12 Bronchodilators market driver impact
Fig. 13 Bronchodilators market restraint impact
Fig. 14 Porter’s five forces analysis
Fig. 15 Bronchodilators market: Drug type outlook and key takeaways
Fig. 16 Beta-adrenergic bronchodilators market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Anticholinergic bronchodilators market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Xanthine derivative market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Bronchodilators market: Cancer type outlook and key takeaways
Fig. 20 Bronchodilators market: Route of administration movement analysis
Fig. 21 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Nasal (Inhalation) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Bronchodilators market: Disease outlook and key takeaways
Fig. 25 Bronchodilators market: Disease movement analysis
Fig. 26 Asthma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Chronic obstructive pulmonary disease (COPD) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Bronchodilators Market: Regional outlook and key takeaways
Fig. 30 Bronchodilators Market: Regional movement analysis
Fig. 31 North America
Fig. 32 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 U.S.
Fig. 34 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Canada
Fig. 36 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Europe
Fig. 38 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 U.K.
Fig. 40 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Germany
Fig. 42 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 France
Fig. 44 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Spain
Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Italy
Fig. 48 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Denmark
Fig. 50 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Sweden
Fig. 52 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Norway
Fig. 54 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Asia Pacific
Fig. 56 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Japan
Fig. 58 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 China
Fig. 60 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 India
Fig. 62 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Thailand
Fig. 64 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Australia
Fig. 66 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 South Korea
Fig. 68 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Latin America
Fig. 70 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Brazil
Fig. 72 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Mexico
Fig. 74 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Argentina
Fig. 76 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 MEA
Fig. 78 MEA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 South Africa
Fig. 80 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Saudi Arabia
Fig. 82 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 UAE
Fig. 84 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Kuwait
Fig. 86 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Ansoff Matrix
Fig. 88 Strategy mapping
Fig. 89 Company market share analysis, 2022
Fig. 90 Heat Map Analysis
Fig. 91 Market differentiators
Fig. 92 Heat Map Analysis
Companies Mentioned
- Gsk Plc.
- Astrazeneca
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Mylan N.V.
- Merck & Co., Inc.
- Novartis Ag
- Boehringer Ingelheim International Gmbh.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | January 2023 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 22.77 Billion |
| Forecasted Market Value ( USD | $ 28.75 Billion |
| Compound Annual Growth Rate | 3.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
